Enigmatic Achromobacter | CMAC

Enigmatic Achromobacter

Clinical Microbiology and Antimicrobial Chemotherapy. 2022; 24(1):4-13

​ Chebotar I.V., Bocharova Yu.A.
10.36488/cmac.2022.1.4-13
Achromobacter antimicrobial resistance diagnosis infection
Section
Diseases and Pathogens
Type
Review
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2022; 24(1):4-13

Abstract

This review aims to describe the microbiological characteristics, resistant features and pathogenic potential of Achromobacter spp. Achromobacter as an opportunistic pathogen can cause severe and even fatal infections. The current knowledge about molecular basis of clinically significant traits of Achromobacter spp. was critically analyzed. The understanding of pathogenicity factors of Achromobacter spp. are largely based on predictive analysis and the role of the most factors was not confirmed by in vivo and in vitro studies. Achromobacter spp. are intrinsically resistant to many groups of antibiotics and can rapidly acquire an adaptive antibiotic resistance. Only three antibiotics (meropenem, piperacillin/tazobactam, and trimethoprim/sulfamethoxazole) have the established breakpoints for Achromobacter spp. There is an unmet need to develop available and accurate methods for species identification of Achromobacter spp.

Igor V. Chebotar

Pirogov Russian National Research Medical University, Moscow, Russia

Bocharova Yu.A.

Pirogov Russian National Research Medical University, Moscow, Russia

  • 1. Somayaji R., Stanojevic S., Tullis D.E., Stephenson A.L., Ratjen F., Waters V. Clinical outcomes associated with Achromobacter species infection in patients with cystic fibrosis. Ann Am Thorac Soc. 2017;14(9):1412-1418. DOI: 10.1513/AnnalsATS.201701-071OC
  • 2. Marsac C., Berdah L., Thouvenin G., Sermet-Gaudelus I., Corvol H. Achromobacter xylosoxidans airway infection is associated with lung disease severity in children with cystic fibrosis. ERJ Open Research. 2021;7(2):00076-2021. DOI: 10.1183/23120541.00076-2021
  • 3. Swenson C.E., Sadikot R.T. Achromobacter respiratory infections. Ann Am Thorac Soc. 2015;12:252-258. DOI: 10.1513/AnnalsATS.201406-288FR
  • 4. Marion-Sanchez K., Lion F., Olive C., Cailleaux G., Roques F. Mediastinitis superinfected by Achromobacter xylosoxidans. A case report. J Infect Chemother. 2018;24:987-989. DOI: 10.1016/j.jiac.2018.05.005
  • 5. Asano K., Tada S., Matsumoto T., Miyase S., Kamio T., KSakurai K., Lida M. A novel bacterium Achromobacter xylosoxidans as a cause of liver abscess: three case reports. J Hepatol. 2005;43:362-365. DOI: 10.1016/j.jhep.2005.03.031
  • 6. Ronin E., Derancourt C., Cabié A., Marion-Sanchez K. Achromobacter spp. Surgical site infections: a systematic review of case reports and case series. Microorganisms. 2021;9(12):2471. DOI: 10.3390/microorganisms9122471
  • 7. Bergey D.H., Harrison F.C., Breed R.S., Hammer B.W., Huntoon F.M. Bergey’s manual of determinative bacteriology. 1st Ed. The Williams & Wilkins Co, Baltimore; 1923. 442 p.
  • 8. Eisenberg J. Bakteriologische Diagnostik, Hilfstabellen zum Gebrauche beim Praktischen Arbeiten. 3 Aufl. Leopold Voss, Hamburg; 1891. 509 S.
  • 9. Lehmann K.B., Neumann R.O. Atlas und Grundriss der Bakteriologie und Lehrbuch der speciellen bacteriologischen Diagnostik. Teil II. Verlag von Lehmann J.F., Munich; 1896. 448 S.
  • 10. Wells N.A., ZoBell C.E. Achromobacter ichthyodermis, n. sp., the etiological agent of an infectious dermatitis of certain marine fishes. Proc Natl Acad Sci U S A. 1934;20(2):123-126. DOI: 10.1073/pnas.20.2.123
  • 11. Dereux J. Lymphocytic meningitis caused by a germ of the family Achromobacteriaceae. Bull Acad Natl Med. 1954;138(7-8):118-120. PMID: 13160586
  • 12. Krieg N.R. Holt J.G. Bergey’s Manual of Systematic Bacteriology. 1st Ed., Vol. 1. Williams and Wilkins, Baltimore; 1984. 964 p.
  • 13. Buchanan R.E., Gibbons N.R. Bergey's Manual of Determinative Bacteriology. 8th Ed., Williams & Wilkins, Baltimore; 1974. 1268 p.
  • 14. Busse H.-J., Auling G. Achromobacter. In: Bergey’s Manual of Systematics of Archaea and Bacteria; 2015. DOI: 10.1002/9781118960608.gbm00926
  • 15. International Committee on Systematics of Prokaryotes (ICSP). Available at: www.the-icsp.org. Accessed January 2022.
  • 16. International code of nomenclature of Prokaryotes. Int J Syst Evol Microbiol. 2019;69(1A):S1-S111. DOI: 10.1099/ijsem.0.000778
  • 17. Vandamme P., Moore E.R.B., Cnockaert M., Peeters C., Svensson-Stadler L., Houf K., et al. Classification of Achromobacter genogroups 2, 5, 7 and 14 as Achromobacter insuavis sp. nov., Achromobacter aegrifaciens sp. nov., Achromobacter anxifer sp. nov. and Achromobacter dolens sp. nov., respectively. Syst Appl Microbiol. 2013;36(7):474-482. DOI: 10.1016/j.syapm.2013.06.005
  • 18. Vandamme P., Moore E.R.B., Cnockaert M., De Brandt E., Svensson-Stadler L., Houf K., et al. Achromobacter animicus sp. nov., Achromobacter mucicolens sp. nov., Achromobacter pulmonis sp. nov. and Achromobacter spiritinus sp. nov., from human clinical samples. Syst Appl Microbiol. 2013;36(1):1-10. DOI: 10.1016/j.syapm.2012.10.003
  • 19. Vandamme P.A., Peeters C., Inganäs E., Cnockaert M., Houf K., Spilker T., et al. Taxonomic dissection of Achromobacter denitrificans Coenye et al. 2003 and proposal of Achromobacter agilis sp. nov., nom. rev., Achromobacter pestifer sp. nov., nom. rev., Achromobacter kerstersii sp. nov. and Achromobacter deleyi sp. nov. Int J Syst Evol Microbiol. 2016;66(9):3708-3717. DOI: 10.1099/ijsem.0.001254
  • 20. Coenye T., Vancanneyt M., Cnockaert M.C., Falsen E., Swings J., Vandamme P. Kerstersia gyiorum gen. nov., sp. nov., a novel Alcaligenesfaecalis-like organism isolated from human clinical samples, and reclassification of Alcaligenes denitrificans Ruger and Tan 1983 as Achromobacter denitrificans comb. nov. Int J Syst Evol Microbiol. 2003;53:1825-1831. DOI: 10.1099/ijs.0.02609-0
  • 21. Coenye T., Vancanneyt M., Falsen E., Swings J., Vandamme P. Achromobacter insolitus sp. nov. and Achromobacter spanius sp. nov., from human clinical samples. Int J Syst Evol Microbiol. 2003;53:1819-1824. DOI: 10.1099/ijs.0.02698-0
  • 22. Gomila M., Tvrzová L., Teshim A., Sedlácek I., GonzálezEscalona N., González-Escalona N., et al. Achromobacter marplatensis sp. nov., isolated from a pentachlorophenolcontaminated soil. Int J Syst Evol Microbiol. 2011;61:22312237. DOI: 10.1099/ijs.0.025304-0
  • 23. Yabuuchi E., Kawamura Y., Kosako Y., Ezaki T. Emendation of genus Achromobacter and Achromobacter xylosoxidans (Yabuuchi and Yano) and proposal of Achromobacter ruhlandii (packer and Vishniac) comb. nov., Achromobacter piechaudii (Kiredjian et al.) comb. nov., and Achromobacter xylosoxidans subsp. denitrificans (Rüger and Tan) comb. nov. Microbiol Immunol. 1998;42(6):429-438. DOI: 10.1111/j.1348-0421.1998.tb02306.x
  • 24. Kazemzadeh S., Naghavi N.S., Emami-Karvani Z., Emtiazi G., Fouladgar M. Production of glycolipid biosurfactant during crude oil degradation by the novel indigenous isolated Achromobacter kerstersii LMG3441. Water Sci Technol. 2020;82(10):2134-2147. DOI: 10.2166/wst.2020.474
  • 25. Genome Taxonomy Database (GTDB). Available at: https://gtdb.ecogenomic.org/. Accessed January 2022.
  • 26. Abdouchakour F., Dupont C., Grau D., Aujoulat F., Mournetas P., Marchandin H., et al. Pseudomonas aeruginosa and Achromobacter sp. clonal selection leads to successive waves of contamination of water in dental care units. Appl Environ Microbiol. 2015;81(21):7509-7524. DOI: 10.1128/AEM.01279-15
  • 27. McBain A.J., Bartolo R.G., Catrenich C.E., Charbonneau D., Ledder R.G., Price B.B., Gilbert P. Exposure of sink drain microcosms to triclosan: population dynamics and antimicrobial susceptibility. Appl Environ Microbiol. 2003;69(9):5433-5442. DOI: 10.1128/AEM.69.9.5433-5442.2003
  • 28. Amoureux L., Bador J., Fardeheb S., Mabille C., Couchot C., Massip C., et al. Detection of Achromobacter xylosoxidans in hospital, domestic, and outdoor environmental samples and comparison with human clinical isolates. Appl Environ Microbiol. 2013;79(23):7142-7149. DOI: 10.1128/AEM.02293-13
  • 29. Edwards B.D., Greysson-Wong J., Somayaji R., Waddell B., Whelan F.J., Storey D.G., et al. Prevalence and outcomes of Achromobacter species infections in adults with cystic fibrosis: a North American cohort study. J Clin Microbiol. 2017;55(7):2074-2085. DOI: 10.1128/JCM.02556-16
  • 30. Filipic B., Malesevic M., Vasiljevic Z., Lukic J., Novovic K., Kojic M., Jovcic B. Uncovering differences in virulence markers associated with Achromobacter species of CF and non-CF origin. Front Cell Infect Microbiol. 2017;7:224. DOI: 10.3389/fcimb.2017.00224
  • 31. Vijay A.K., Willcox M.D. Adhesion of Stenotrophomonas maltophilia, Delftia acidovorans, and Achromobacter xylosoxidans to contact lenses. Eye Contact Lens. 2018;44:S120-S126. DOI: 10.1097/ICL.0000000000000425
  • 32. Nejidat A., Saadi I., Ronen Z. Effect of flagella expression on adhesion of Achromobacter piechaudii to chalk surfaces. J Appl Microbiol. 2008;105(6):2009-2014. DOI: 10.1111/j.1365-2672.2008.03930.x
  • 33. Mantovani R.P., Levy C.E., Yano T. A heat-stable cytotoxic factor produced by Achromobacter xylosoxidans isolated from Brazilian patients with CF is associated with in vitro increased proinflammatory cytokines. J Cyst Fibros. 2012;11(4):305-311. DOI: 10.1016/j.jcf.2012.02.002
  • 34. Veschetti L., Sandri A., Patuzzo C., Melotti P., Malerba G., Lleo M.M. Genomic characterization of Achromobacter species isolates from chronic and occasional lung infection in cystic fibrosis patients. Microb Genom. 2021;7(7):000606. DOI: 10.1099/mgen.0.000606
  • 35. Virulence Factor Database (VFDB). Available at: www.mgc.ac.cn/VFs. Accessed January 2022.
  • 36. Rapid Annotations using Subsystems Technology (RAST). Available at: http://RAST.nmpdr.org/. Accessed January 2022.
  • 37. Hansen C.R., Pressler T., Nielsen K.G., Jensen P.Ø., Bjarnsholt T., Høiby N. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst Fibros. 2010;9(1):51-58. DOI: 10.1016/j.jcf.2009.10.005
  • 38. Jakobsen T.H., Hansen M.A., Jensen P.Ø., Hansen L., Riber L., Cockburn A., et al. Complete genome sequence of the cystic fibrosis pathogen Achromobacter xylosoxidans NH44784-1996 complies with important pathogenic phenotypes. PloS One. 2013;8(7):e68484. DOI: 10.1371/journal.pone.0068484
  • 39. Veschetti L., Sandri A., Krogh Johansen H., Lleò M.M., Malerba G. Hypermutation as an evolutionary mechanism for Achromobacter xylosoxidans in cystic fibrosis lung infection. Pathogens. 2020;9(2):72. DOI: 10.3390/pathogens9020072
  • 40. Ridderberg W., Nielsen S.M., Nørskov-Lauritsen N. Genetic adaptation of Achromobacter sp. during persistence in the lungs of cystic fibrosis patients. PLoS One. 2015;10(8):e0136790. DOI: 10.1371/journal.pone.0136790
  • 41. Li X., Hu Y., Gong J., Zhang L., Wang G. Comparative genome characterization of Achromobacter members reveals potential genetic determinants facilitating the adaptation to a pathogenic lifestyle. Appl Microbiol Biotechnol. 2013;97(14):6413-6425. DOI: 10.1007/s00253-013-5018-3
  • 42. Tessmer M.H., Anderson D.M., Pickrum A.M., Riegert M.O., Frank D.W. Identification and verification of ubiquitin-activated bacterial phospholipases. J Bacteriol. 2019;201(4):e00623-18. DOI: 10.1128/JB.00623-18
  • 43. Pickrum A.M., DeLeon O., Dirck A., Tessmer M.H., Riegert M.O., Biller J.A., et al. Achromobacter xylosoxidans cellular pathology is correlated with activation of a type III secretion system. Infect Immun. 2020;88(7):e00136-20. DOI: 10.1128/IAI.00136-20
  • 44. Isogai H., Isogai E., Fujii N., Oguma K., Chang K.L., Deguchi E., et al. Biological effects of lipopolysaccharide from Achromobacter stenohalis on lymphocytes and macrophages. Nihon Juigaku Zasshi. 1989;51(5):1003-1010. DOI: 10.1292/jvms1939.51.1003
  • 45. Orellana-Peralta F., Jacinto M., Pons M.J., Gomes C., Bada C., Reyes I., et al. Characterization of two Achromobacter xylosoxidans isolates from patients with pertussis-like symptoms. Asian Pac J Trop Med. 2015;8(6):464-467. DOI: 10.1016/j.apjtm.2015.05.013
  • 46. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Intrinsic Resistance and Unusual Phenotypes. Version 3.3, October 2021. Available at: www.eucast.org/expert_rules_and_intrinsic_resistance/. Accessed January 2022.
  • 47. Doi Y., Poirel L., Paterson D.L., Nordmann P. Characterization of a naturally occurring classD β-lactamase from Achromobacter xylosoxidans. Antimicrob Agents Chemother. 2008;52(6):1952-1956. DOI: 10.1128/AAC.01463-07
  • 48. Levesque R., Letarte R., Pechère J.-C. Comparative study of the beta-lactamase activity found in Achromobacter. Can J Microbiol. 1983;29(7):819-826. DOI: 10.1139/m83133
  • 49. Decré D., Arlet G., Bergogne-Berezin E., Philippon A. Identification of a carbenicillin-hydrolyzing β-lactamase in Alcaligenes denitrificans subsp. xylosoxydans. Antimicrob Agents Chemother. 1995;39(3):771-774. DOI: 10.1128/AAC.39.3.771
  • 50. Philippon A., Mensah K., Fournier G., Freney J. Two resistance phenotypes to β-lactams of Alcaligenes denitrificans subsp. xylosoxydans in relation to β-lactamase types. J Antimicrob Chemother. 1990;25(4):698-700. DOI: 10.1093/jac/25.4.698
  • 51. Fujii T., Sato K., Inoue M., Mitsuhashi S. Purification and properties of a β-lactamase from Alcaligenes dentrificans subsp. xylosoxydans. J Antimicrob Chemother. 1985;16(3):297-304. DOI: 10.1093/jac/16.3.297
  • 52. Bador J., Amoureux L., Duez J.M., Drabowicz A., Siebor E., Llanes C., Neuwirth C. First description of an RND-type multidrug efflux pump in Achromobacter xylosoxidans, AxyABM. Antimicrob Agents Chemother. 2011;55(10):4912-4914. DOI: 10.1128/AAC.00341-11
  • 53. Bador J., Amoureux L., Blanc E., Neuwirth C. Innate aminoglycoside resistance of Achromobacter xylosoxidans is due to AxyXY-OprZ, an RND-type multidrug efflux pump. Antimicrob Agents Chemother. 2013;57(1):603-605. DOI: 10.1128/AAC.01243-12
  • 54. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 12.0, 2022. Available at: www.eucast.org/clinical_breakpoints/. Accessed January 2022.
  • 55. Manohar P., Leptihn S., Lopes B. S., Nachimuthu R. Dissemination of carbapenem resistance and plasmids encoding carbapenemases in Gram-negative bacteria isolated in India. JAC Antimicrob Resist. 2021;3(1):dlab015. DOI: 10.1093/jacamr/dlab015
  • 56. Potron A., Fournier D., Emeraud C., Triponney P., Plésiat P., Naas T., Dortet L. Evaluation of the immunochromatographic NG-Test Carba 5 for rapid identification of carbapenemase in nonfermenters. Antimicrob Agents Chemother. 2019;63(9):e00968-19. DOI: 10.1128/AAC.00968-19
  • 57. Vali P., Shahcheraghi F., Seyfipour M., Zamani M.A., Allahyar M.R., Feizabadi M.M. Phenotypic and genetic characterization of carbapenemase and ESBLs producing gram-negative bacteria (GNB) isolated from patients with cystic fibrosis (CF) in Tehran hospitals. J Clin Diagn Res. 2014;8(1):26-30. DOI: 10.7860/JCDR/2014/6877.3916
  • 58. Yamamoto M., Matsumura Y., Gomi R., Matsuda T., Tanaka M., Nagao M., et al. Interspecies dissemination of a mobilizable plasmid harboring bla IMP-19 and the possibility of horizontal gene transfer in a single patient. Antimicrob Agents Chemother. 2016;60(9):5412-5419. DOI: 10.1128/AAC.00933-16
  • 59. Chen Z., Fang H., Wang L., Sun F., Wang Y., Yin Z., et al. IMP-1 encoded by a novel Tn 402-like class 1 integron in clinical Achromobacter xylosoxidans, China. Sci Rep. 2014;4:7212. DOI: 10.1038/srep07212
  • 60. Fleurbaaij F., Henneman A.A., Corver J., Knetsch C.W., Smits W.K., Nauta S.T., et al. Proteomic identification of Axc, a novel beta-lactamase with carbapenemase activity in a meropenem-resistant clinical isolate of Achromobacter xylosoxidans. Sci Rep. 2018;8:8181. DOI: 10.1038/s41598-018-26079-z
  • 61. Traglia G.M., Almuzara M., Merkier A K., Adams C., Galanternik L., Vay C., et al. Achromobacter xylosoxidans: an emerging pathogen carrying different elements involved in horizontal genetic transfer. Curr Microbiol. 2012;65(6):673-678. DOI: 10.1007/s00284-0120213-5
  • 62. Khademi S.H., Gabrielaite M., Paulsson M., Knulst M., Touriki E., Marvig R.L., et al. Genomic and phenotypic evolution of Achromobacter xylosoxidans during chronic airway infections of patients with cystic fibrosis. mSystems. 2021;6(3):e00523-21. DOI: 10.1128/mSystems.00523-21
  • 63. Miller A.K., Brannon M.K., Stevens L., Johansen H.K., Selgrade S.E., Miller S.I., et al. PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients. Antimicrob Agents Chemother. 2011;55(12):5761-5769. DOI: 10.1128/AAC.05391-11
  • 64. Fabbri A., Tacchella A., Manno G., Viscoli C., Palmero C., Gargani G.F. Emerging microorganisms in cystic fibrosis. Chemioterapia. 1987;6(1):32-37. PMID: 3103930
  • 65. Elborn J.S. Cystic fibrosis. Lancet. 2016;388(10059):25192531. DOI: 10.1016/S0140-6736(16)00576-6
  • 66. Karanth S.S., Gupta A., Prabhu M. Community acquired bilateral upper lobe pneumonia with acute adrenal insufficiency: a new face of Achromobacter xylosoxidans. Australas Med J. 2012;5(10):531-533. DOI: 10.4066/AMJ.2012.1279
  • 67. Shimamura T., Yamashita S., Ryuujin S., Ogata T., Yamashita T., Sato A., Hitomi S. Hematogenous pleural infection caused by Achromobacter xylosoxidans in a patient undergoing maintenance hemodialysis. J Infect Chemother. 2020;26(4):389-392. DOI: 10.1016/j.jiac.2019.11.006
  • 68. Tena D., González-Praetorius A., Pérez-Balsalobre M., Sancho O., Bisquert J. Urinary tract infection due to Achromobacter xylosoxidans: report of 9 cases. Scand J Infect Dis. 2008;40(2):84-87. DOI: 10.1080/00365540701558714
  • 69. Sgrelli A., Mencacci A., Fiorio M., Orlandi C., Baldelli F., De Socio G.V. Achromobacter denitrificans renal abscess. New Microbiol. 2012;35(2):245-247. PMID: 22707140
  • 70. Vinod V., Kumar A., Sanjeevan K.V., Dinesh K.R., Karim S. Perinephric abscess due to Achromobacter xylosoxidans following de-roofing of renal cyst. Surg Infect (Larchmt). 2013;14(4):422-423. DOI: 10.1089/sur.2012.142
  • 71. Al-Jasser A.M., Al-Anazi K.A. Complicated septic shock caused by Achromobacter xylosoxidans bacteremia in a patient with acute lymphoblastic leukaemia. Libyan J Med. 2007;2(4):218-219. DOI: 10.4176/070617
  • 72. Turel O., Kavuncuoglu S., Hosaf E., Ozbek S., Aldemir E., Uygur T., et al. Bacteremia due to Achromobacter xylosoxidans in neonates: clinical features and outcome. Braz J Infect Dis. 2013;17(4):450-454. DOI: 10.1016/j.bjid.2013.01.008
  • 73. Nichols K.R., Knoderer C.A., Jackson N.G., Manaloor J.J., Christenson J.C. Success with extended-infusion meropenem after recurrence of baclofen pumprelated Achromobacter xylosoxidans meningitis in an adolescent. J Pharm Pract. 2015;28(4):430-433. DOI: 10.1177/0897190015585757
  • 74. Rovlias A. A rare case of Achromobacter species subdural empyema and brain abscess in an adult patient with hematologic malignancy. Asian J Neurosurg. 2020;5(1):245-246. DOI: 10.4103/ajns.AJNS_373_19
  • 75. Eshwara V.K., Mukhopadhyay C., Mohan S., Prakash R., Pai G. Two unique presentations of Achromobacter xylosoxidans infections in clinical settings. J Infect Dev Ctries. 2011;5(2):138-141. DOI: 10.3855/jidc.1258
  • 76. Crosby M.D., Petropolis A.A., Mackey V.T., Culpepper K.S. An unusual skin infection with Achromobacter xylosoxidans. Cutis. 2020;106(4):2110-2112. DOI: 10.12788/cutis.0087
  • 77. Tena D., Martínez N.M.., Losa C., Solís S. Skin and soft tissue infection caused by Achromobacter xylosoxidans: report of 14 cases. Scand J Infect Dis. 2014;46(2):130135. DOI: 10.3109/00365548.2013.857043
  • 78. Alkindi S., Matwani S., Al-Maawali A., Al-Maskari B., Pathare A. Complications of PORT-A-CATH® in patients with sickle cell disease. J Infect Public Health. 2012;5(1):5762. DOI: 10.1016/j.jiph.2011.10.004
  • 79. Ahmed M.S., Nistal C., Jayan R., Kuduvalli M., Anijeet H.K. Achromobacter xylosoxidans, an emerging pathogen in catheter-related infection in dialysis population causing prosthetic valve endocarditis: a case report and review of literature. Clin Nephrol. 2009;71(3):350-354. DOI: 10.5414/cnp71350
  • 80. de Castro R.L., de Alcantara Lima N., da Costa Lino D.O., Melgar T.A. A rare case of non-prosthetic aortic valve infectious endocarditis caused by Achromobacter xylosoxidans. Am J Case Rep. 2020;21:e923031-1. DOI: 10.12659/AJCR.923031
  • 81. Van Hal S., Stark D., Marriott D., Harkness J. Achromobacter xylosoxidans subsp. xylosoxidans prosthetic aortic valve infective endocarditis and aortic root abscesses. J Med Microbiol. 2008;57(4):525-527. DOI: 10.1099/jmm.0.47496-0
  • 82. Bc D., Bernard S.H., Vv V., Gp W., Jm J. The role of Achromobacter xylosoxidans positive sinus cultures in patients with refractory chronic rhinosinusitis. Online J Otolaryngol. 2018;8(2):172.
  • 83. Cheong R.C.T., Harding L. Septic arthritis of the temporomandibular joint secondary to acute otitis media in an adult: a rare case with Achromobacter xylosoxidans. Case Rep Otolaryngol. 2017;2017:3641642. DOI: 10.1155/2017/3641642
  • 84. Lazzarini T.A., Al-Khersan H., Patel N.A., Yannuzzi N.A., Martinez J.D., Altamirano D., et al. Chronic, recurrent bacterial endophthalmitis caused by Achromobacter xylosoxidans: clinical features and management. Int Med Case Rep J. 2020;13:265-269. DOI: 10.2147/IMCRJ.S259899
  • 85. Spierer O., Monsalve P.F., O’Brien T.P., Alfonso E.C., Gologorsky D., Miller D. Clinical features, antibiotic susceptibility profiles, and outcomes of infectious keratitis caused by Achromobacter xylosoxidans. Cornea. 201;35(5):626-630. DOI: 10.1097/ICO.0000000000000798
  • 86. Cankaya E., Keles M., Gulcan E., Uyanik A., Uyanik H. A rare cause of peritoneal dialysis-related peritonitis: Achromobacter denitrificans. Perit Dial Int. 2014;34(1):135137. DOI: 10.3747/pdi.2013.00063
  • 87. Kawaguchi Y., Hayashi S., Kawagoe N., Igawa T. Retroperitoneal abscess due to Achromobacter xylosoxidans presenting as femoral pain. Urol Case Rep. 2020;31:101153. DOI: 10.1016/j.eucr.2020.101153
  • 88. Barton L.L., Hoddy D.M. Osteomyelitis due to Achromobacter xylosoxidans. Clin Infect Dis. 1993;17(2):296-297. DOI: 10.1093/clinids/17.2.296
  • 89. Carroll M.B., Forgione M. Achromobacter xylosoxidans presenting as a suprapatellar abscess and polyarthritis. J Clin Rheumatol. 2010;16(1):45-46. DOI: 10.1097/RHU.0b013e3181c7e4c8
  • 90. Patel P.K., von Keudell A., Moroder P., Appleton P., Wigmore R., Rodriguez E.K. Recurrent septic arthritis due to Achromobacter xylosoxidans in a patient with granulomatosis with polyangiitis. Open Forum Infect Dis. 2015;2(4):ofv145. DOI: 10.1093/ofid/ofv145
  • 91. Haviari S., Cassier P., Dananché C., Hulin M., Dauwalder O., Rouvière O., et al. Outbreak of Achromobacter xylosoxidans and Ochrobactrum anthropi infections after prostate biopsies, France, 2014. Emerg Infect Dis. 2016;22(8):1412-1419. DOI: 10.3201/eid2208.151423
  • 92. Papalia M., Steffanowski C., Traglia G., Almuzara M., Martina P., Galanternik L., et al. Diversity of Achromobacter species recovered from patients with cystic fibrosis, in Argentina. Rev Argent Microbiol. 2020;52(1):13-18. DOI: 10.1016/j.ram.2019.03.004
  • 93. Rotter J., Graffeo C.S., Perry A., Gilder H.E., Wilson J.W., Link M.J. Polymicrobial intracerebral abscess growing Mycobacterium avium complex and Achromobacter xylosoxidans: case report and literature review. World Neurosurg. 2020;141:441-447. DOI: 10.1016/j.wneu.2020.05.283
  • 94. Sandri A., Haagensen J.A.J., Veschetti L., Johansen H.K., Molin S., Malerba G., et al. Adaptive interactions of Achromobacter spp. with Pseudomonas aeruginosa in cystic fibrosis chronic lung co-infection. Pathogens. 2021;10(8):978. DOI: 10.3390/pathogens10080978
  • 95. Habib S., Fuca N., Azam M., Siddiqui A.H., Rajdev K., Chalhoub M. Achromobacter xylosoxidans/denitrificans bacteremia and subsequent fatal Escherichia coli/Streptococcus anginosus pleural empyema. Respir Med Case Rep. 2018;25:311-313. DOI: 10.1016/j.rmcr.2018.10.010
  • 96. Garrigos T., Neuwirth C., Chapuis A., Bador J., Amoureux L., Collaborators. Development of a database for the rapid and accurate routine identification of Achromobacter species by matrix-assisted laser desorption/ionization–timeof-flight mass spectrometry (MALDI-TOF MS). Clin Microbiol Infect. 2021;27(1):126.e1-126.e5. DOI: 10.1016/j.cmi.2020.03.031
  • 97. Spilker T., Vandamme P., Lipuma J.J. Identification and distribution of Achromobacter species in cystic fibrosis. J Cyst Fibros. 2013;12:298-301. DOI: 10.1016/j.jcf.2012.10.002
  • 98. Spilker T., Vandamme P. and Lipuma J.J. A multilocus sequence typing scheme implies population structure and reveals several putative novel Achromobacter species. J Clin Microbiol. 2012;50(9):3010-3015. DOI: 10.1128/JCM.00814-12
Views
0 Abstract
0 PDF
0 Crossref citations
Shared